Topical Combination Agent for Plaque Psoriasis Showed Superiority to Monotherapies in PIII Trial: Maruho

November 19, 2014
Maruho announced on November 18 that the topical combination drug M8010 (maxacalcitol + betamethasone butyrate propionate), a treatment for plaque psoriasis, which Maruho is codeveloping with Chugai Pharmaceutical, demonstrated superiority to maxacalcitol and betamethasone butyrate propionate monotherapies and met its...read more